[go: up one dir, main page]

SG11201607058PA - Aromatic heterocyclic compounds as antiinflammatory compounds - Google Patents

Aromatic heterocyclic compounds as antiinflammatory compounds

Info

Publication number
SG11201607058PA
SG11201607058PA SG11201607058PA SG11201607058PA SG11201607058PA SG 11201607058P A SG11201607058P A SG 11201607058PA SG 11201607058P A SG11201607058P A SG 11201607058PA SG 11201607058P A SG11201607058P A SG 11201607058PA SG 11201607058P A SG11201607058P A SG 11201607058PA
Authority
SG
Singapore
Prior art keywords
compounds
aromatic heterocyclic
antiinflammatory
heterocyclic compounds
antiinflammatory compounds
Prior art date
Application number
SG11201607058PA
Inventor
Alistair Ian Longshaw
Euan Alexander Fraser Fordyce
Stuart Thomas Onions
John King-Underwood
Jennifer Diane Venable
Original Assignee
Respivert Ltd
Topivert Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivert Ltd, Topivert Pharma Ltd filed Critical Respivert Ltd
Publication of SG11201607058PA publication Critical patent/SG11201607058PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201607058PA 2014-02-14 2015-02-13 Aromatic heterocyclic compounds as antiinflammatory compounds SG11201607058PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461940282P 2014-02-14 2014-02-14
US201461941064P 2014-02-18 2014-02-18
PCT/EP2015/053151 WO2015121444A1 (en) 2014-02-14 2015-02-13 Aromatic heterocyclic compounds as antiinflammatory compounds

Publications (1)

Publication Number Publication Date
SG11201607058PA true SG11201607058PA (en) 2016-10-28

Family

ID=52573661

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607058PA SG11201607058PA (en) 2014-02-14 2015-02-13 Aromatic heterocyclic compounds as antiinflammatory compounds

Country Status (20)

Country Link
US (8) US9884845B2 (en)
EP (4) EP3418279B1 (en)
JP (4) JP6586098B2 (en)
KR (1) KR102413704B1 (en)
CN (4) CN106164067B (en)
AU (3) AU2015216957B2 (en)
BR (1) BR112016015838B1 (en)
CA (1) CA2938924C (en)
DK (2) DK3105222T3 (en)
EA (1) EA034927B1 (en)
ES (2) ES2677595T3 (en)
JO (1) JO3392B1 (en)
MX (2) MX371353B (en)
PL (2) PL3105222T3 (en)
PT (2) PT3357919T (en)
SG (1) SG11201607058PA (en)
TR (1) TR201809072T4 (en)
TW (2) TWI664967B (en)
UY (1) UY35998A (en)
WO (2) WO2015121444A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945869B (en) 2007-12-19 2014-06-18 癌症研究技术有限公司 Pyrido[2,3-B]pyrazine-8-substituted compounds and uses thereof
WO2011092469A1 (en) 2010-02-01 2011-08-04 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
US9108950B2 (en) 2011-10-03 2015-08-18 Respivert, Ltd. 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
EP2890701B1 (en) 2012-08-29 2017-03-29 Respivert Limited Kinase inhibitors
US20150210722A1 (en) 2012-08-29 2015-07-30 Respivert Limited Kinase inhibitors
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
WO2014140582A1 (en) 2013-03-14 2014-09-18 Respivert Limited Kinase inhibitors
DK2981535T3 (en) 2013-04-02 2021-03-01 Oxular Acquisitions Ltd URINE DERIVATIVES USE AS CHINESE INHIBITORS
WO2014162121A1 (en) 2013-04-02 2014-10-09 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
EP3083604A1 (en) 2013-12-20 2016-10-26 Respivert Limited Urea derivatives useful as kinase inhibitors
TWI664967B (en) 2014-02-14 2019-07-11 英商瑞斯比維特有限公司 Novel compound
MA40775A (en) 2014-10-01 2017-08-08 Respivert Ltd 4- (4- (4-PHENYLUREIDO-NAPHTALÉN -1-YL) OXY-PYRIDIN-2-YL) AMINO-BENZOIC ACID USED AS A KINASE P38 INHIBITOR
CN105801486A (en) * 2016-03-31 2016-07-27 常州大学 Synthetic method of 1-(2,4 dibromophenyl)-3-pyrazol alcohol
EP3440073B1 (en) 2016-04-06 2022-06-08 Oxular Acquisitions Limited Kinase inhibitors
CN109640970B (en) * 2016-06-23 2023-05-23 马里兰大学巴尔的摩分校 Selective p38α-specific MAPK inhibitor
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (en) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
MX2021006731A (en) 2018-12-07 2021-09-23 Univ Maryland NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS.
WO2020154350A1 (en) * 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
JP7495526B2 (en) 2020-05-18 2024-06-04 ジーニー ライフサイエンシズ インコーポレイテッド P38 alpha mitogen-activated protein kinase inhibitors
CN111889025B (en) * 2020-09-01 2022-01-11 山东大学 Acid-alkali-resistant salt-resistant super-amphiphilic molecule emulsifier, preparation method thereof and emulsion
JP2023546835A (en) 2020-10-29 2023-11-08 ジーニー ライフサイエンシズ インコーポレイテッド Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide dihydrochloride dihydrate
US20240307374A1 (en) * 2021-02-03 2024-09-19 Bp Asset V. Inc. Formulation of furin inhibitor for inhalation
IL306101A (en) * 2021-03-23 2023-11-01 Gen1E Lifesciences Inc Substituted naphthyl p38 alpha mitogen-activated protein kinase inhibitors
CN116655608B (en) * 2023-05-30 2025-08-19 成都瑞芬思德丹生物科技有限公司 Pyrrolidone compound with anti-inflammatory activity and preparation method and application thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002617T2 (en) 1997-12-22 2000-11-21 Bayer Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
DE69836563T2 (en) 1997-12-22 2007-05-16 Bayer Pharmaceuticals Corp., West Haven INHIBITION OF p38 KINASE ACTIVITY THROUGH THE USE OF ARYL AND HETEROARYL SUBSTITUTED UREAS
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE60024830T2 (en) 1999-07-09 2006-06-14 Boehringer Ingelheim Pharma METHOD FOR PRODUCING HETEROARYL SUBSTITUTED UREA BONDING
EP1232150B1 (en) 1999-11-16 2007-10-10 Boehringer Ingelheim Pharmaceuticals Inc. Urea derivatives as anti-inflammatory agents
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
DK1259485T3 (en) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamides and related inhibitors of factor Xa
MXPA03010487A (en) 2001-05-16 2004-03-09 Boehringer Ingelheim Pharma Diarylurea derivatives useful as anti-inflammatory agents.
EP1408950B1 (en) 2001-07-11 2007-04-25 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating cytokine mediated diseases
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
ES2299689T3 (en) 2002-02-25 2008-06-01 Boehringer Ingelheim Pharmaceuticals Inc. FUSIONED CYCLALQUIL-UERA COMPOUNDS WITH 1,4-DISPOSED BENZO, USEFUL FOR THE TREATMENT OF ILLNESSES BY CYTOKINES.
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
EP1541563A4 (en) 2002-07-10 2007-11-07 Ono Pharmaceutical Co Ccr4 antagonist and medicinal use thereof
ATE489379T1 (en) 2003-02-28 2010-12-15 Bayer Healthcare Llc 2-OXO-1,3,5-PERHYDROTRIAZAPINE DERIVATIVES SUITABLE FOR THE TREATMENT OF HYPERPROLIFERATIVE, ANGIOGENIC AND INFLAMMATORY DISEASES
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
GB0500435D0 (en) 2005-01-10 2005-02-16 Novartis Ag Organic compounds
ES2352796T3 (en) 2005-06-27 2011-02-23 Bristol-Myers Squibb Company CYCLIC ANTAGONISTS UNITED TO C OF THE P2Y1 RECEIVER USEFUL IN THE TREATMENT OF THROMBOTHIC AFFECTIONS.
EA200900571A1 (en) 2006-10-20 2009-12-30 Айкос Корпорейшн COMPOSITIONS CHK1 INHIBITORS
PT2268623E (en) 2008-03-17 2015-09-17 Ambit Biosciences Corp Quinazoline derivatives as raf kinase modulators and methods of use thereof
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
BRPI0920707A2 (en) 2008-10-02 2015-12-29 Respivert Ltd compounds
AU2009326148B2 (en) * 2008-12-11 2014-05-08 Respivert Limited p38 MAP kinase inhibitors
GB0905955D0 (en) * 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
EP2738161B1 (en) 2010-03-15 2018-04-11 Ube Industries, Ltd. Method for producing amide compound
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
EP2556067B1 (en) 2010-04-08 2016-02-24 Respivert Limited Pyrazolyl ureas as p38 map kinase inhibitors
JP5787977B2 (en) 2010-04-08 2015-09-30 レスピバート・リミテツド P38 MAP kinase inhibitor
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
WO2011158044A2 (en) 2010-06-17 2011-12-22 Respivert Limited Respiratory formulations and compounds for use therein
GB201010196D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Methods
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
US9108950B2 (en) * 2011-10-03 2015-08-18 Respivert, Ltd. 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors
PL2788349T3 (en) 2011-12-09 2017-04-28 Chiesi Farmaceutici S.P.A. Kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
GB201215357D0 (en) * 2012-08-29 2012-10-10 Respivert Ltd Compounds
EP2890701B1 (en) 2012-08-29 2017-03-29 Respivert Limited Kinase inhibitors
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
US20150210722A1 (en) 2012-08-29 2015-07-30 Respivert Limited Kinase inhibitors
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
WO2014140582A1 (en) 2013-03-14 2014-09-18 Respivert Limited Kinase inhibitors
DK2981535T3 (en) 2013-04-02 2021-03-01 Oxular Acquisitions Ltd URINE DERIVATIVES USE AS CHINESE INHIBITORS
WO2014162121A1 (en) 2013-04-02 2014-10-09 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
EP3083604A1 (en) 2013-12-20 2016-10-26 Respivert Limited Urea derivatives useful as kinase inhibitors
TWI664967B (en) * 2014-02-14 2019-07-11 英商瑞斯比維特有限公司 Novel compound
WO2016051186A1 (en) 2014-10-01 2016-04-07 Respivert Limited N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors
MA40775A (en) 2014-10-01 2017-08-08 Respivert Ltd 4- (4- (4-PHENYLUREIDO-NAPHTALÉN -1-YL) OXY-PYRIDIN-2-YL) AMINO-BENZOIC ACID USED AS A KINASE P38 INHIBITOR

Also Published As

Publication number Publication date
KR102413704B1 (en) 2022-06-24
TWI751099B (en) 2022-01-01
CA2939355A1 (en) 2015-08-20
UY35998A (en) 2015-08-31
HK1259444A1 (en) 2019-11-29
US20160368896A1 (en) 2016-12-22
EP3418279A1 (en) 2018-12-26
CA2938924C (en) 2023-01-31
PT3357919T (en) 2020-02-20
US11634406B2 (en) 2023-04-25
CN106164067A (en) 2016-11-23
JP2020055847A (en) 2020-04-09
CN113264921B (en) 2024-09-13
MX371312B (en) 2020-01-24
JP6952085B2 (en) 2021-10-20
JP6586098B2 (en) 2019-10-02
US20210179584A1 (en) 2021-06-17
US10045980B2 (en) 2018-08-14
WO2015121444A1 (en) 2015-08-20
JP6630280B2 (en) 2020-01-15
US9624196B2 (en) 2017-04-18
US9884845B2 (en) 2018-02-06
ES2774249T3 (en) 2020-07-20
BR112016015838B1 (en) 2023-05-09
JP6841891B2 (en) 2021-03-10
ES2677595T3 (en) 2018-08-03
PL3357919T3 (en) 2020-06-01
PT3105222T (en) 2018-07-18
MX2016010572A (en) 2016-11-29
US20170057945A1 (en) 2017-03-02
BR112016015838A2 (en) 2017-08-08
US11142515B2 (en) 2021-10-12
WO2015121660A1 (en) 2015-08-20
CN113264921A (en) 2021-08-17
JP2017505794A (en) 2017-02-23
BR112016015838A8 (en) 2021-07-06
EP3357919A1 (en) 2018-08-08
AU2015216957B2 (en) 2019-04-04
CA2938924A1 (en) 2015-08-20
US20200002311A1 (en) 2020-01-02
US20180118719A1 (en) 2018-05-03
CN106573914B (en) 2021-05-28
CN110522731A (en) 2019-12-03
DK3105222T3 (en) 2018-07-23
AU2015216957A1 (en) 2016-07-14
TW201620518A (en) 2016-06-16
EP3357919B1 (en) 2019-11-20
US20150232450A1 (en) 2015-08-20
PL3105222T3 (en) 2018-09-28
US20170182039A1 (en) 2017-06-29
CN106164067B (en) 2019-09-10
EP3105223A1 (en) 2016-12-21
CN110522731B (en) 2022-08-02
TWI664967B (en) 2019-07-11
JP2020015743A (en) 2020-01-30
JP2017505784A (en) 2017-02-23
KR20160115949A (en) 2016-10-06
EP3105222B1 (en) 2018-04-11
EP3105222A1 (en) 2016-12-21
AU2015216705A1 (en) 2016-08-18
AU2019204525B2 (en) 2021-01-21
TW201620895A (en) 2016-06-16
CN106573914A (en) 2017-04-19
AU2015216705B2 (en) 2019-03-28
TR201809072T4 (en) 2018-07-23
EP3105223B1 (en) 2018-09-12
JO3392B1 (en) 2019-10-20
AU2019204525A1 (en) 2019-07-18
US9447076B2 (en) 2016-09-20
MX371353B (en) 2020-01-27
MX2016010571A (en) 2017-01-05
DK3357919T3 (en) 2020-02-17
US10815217B2 (en) 2020-10-27
EA201691625A1 (en) 2017-01-30
US10294216B2 (en) 2019-05-21
US20190092752A1 (en) 2019-03-28
EP3418279B1 (en) 2021-01-20
EA034927B1 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
SG11201607058PA (en) Aromatic heterocyclic compounds as antiinflammatory compounds
AP2016009297A0 (en) Novel heterocyclic compounds
IL248183A0 (en) Organic compounds
IL248109A0 (en) Organic compounds
IL247018A0 (en) Heterocyclic compound
TWI561516B (en) Substituted dihydroisoquinolinone compounds
IL285105A (en) Heterocyclic compound
IL252578A0 (en) Organic compounds
EP3110819A4 (en) Heterocyclic compounds
IL254424A0 (en) Substituted tricyclic heterocyclic compounds
GB201409044D0 (en) New compounds
GB201404498D0 (en) New compounds
PL3159335T3 (en) Novel heterocyclic compound
GB201416444D0 (en) New compounds
IL252579A0 (en) Organic compounds
GB201415838D0 (en) Organic compounds
GB201412979D0 (en) Organic compounds
GB201416351D0 (en) Heterocyclic derivatives
GB201415845D0 (en) Organic compounds
GB201415565D0 (en) Organic Compounds
GB201401087D0 (en) Organic compounds
GB201417344D0 (en) New compounds
GB201416430D0 (en) New compounds
GB201402647D0 (en) New compounds